These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 36053892)

  • 61. Impact of weight on treatment efficacy and safety in complicated skin and skin structure infections and nosocomial pneumonia caused by methicillin-resistant Staphylococcus aureus.
    Puzniak LA; Morrow LE; Huang DB; Barreto JN
    Clin Ther; 2013 Oct; 35(10):1557-70. PubMed ID: 24011955
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Vancomycin, teicoplanin, daptomycin, and linezolid MIC creep in methicillin-resistant Staphylococcus aureus is associated with clonality.
    Hsieh YC; Lin YC; Huang YC
    Medicine (Baltimore); 2016 Oct; 95(41):e5060. PubMed ID: 27741120
    [TBL] [Abstract][Full Text] [Related]  

  • 63. PK/PD modeling of daptomycin against MRSA and MRSE and Monte Carlo simulation for bacteremia treatment.
    Menezes B; Alves I; Staudt K; Beltrame B; Michelin L; de Araújo BV; Tasso L
    Braz J Microbiol; 2021 Dec; 52(4):1967-1979. PubMed ID: 34337679
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Population Pharmacokinetics Study of Contezolid (MRX-I), a Novel Oxazolidinone Antibacterial Agent, in Chinese Patients.
    Li L; Wu H; Chen Y; Yuan H; Wu J; Wu X; Zhang Y; Cao G; Guo B; Wu J; Zhao M; Zhang J
    Clin Ther; 2020 May; 42(5):818-829. PubMed ID: 32389326
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Optimization of Linezolid Dosing Regimens for Treatment of Vancomycin-Resistant Enterococci Infection.
    Santimaleeworagun W; Changpradub D; Hemapanpairoa J; Thunyaharn S
    Infect Chemother; 2021 Sep; 53(3):503-511. PubMed ID: 34405596
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Population Pharmacokinetic and Pharmacodynamic Analysis for Maximizing the Effectiveness of Ceftobiprole in the Treatment of Severe Methicillin-Resistant Staphylococcal Infections.
    Cojutti PG; Giuliano S; Pascale R; Angelini J; Tascini C; Viale P; Pea F
    Microorganisms; 2023 Dec; 11(12):. PubMed ID: 38138108
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Population pharmacokinetic analysis of linezolid in low body weight patients with renal dysfunction.
    Tsuji Y; Yukawa E; Hiraki Y; Matsumoto K; Mizoguchi A; Morita K; Kamimura H; Karube Y; To H
    J Clin Pharmacol; 2013 Sep; 53(9):967-73. PubMed ID: 23918457
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Activity of linezolid and tedizolid against clinical isolates of methicillin-resistant and methicillin and linezolid resistant Staphylococcus aureus: an in vitro comparison.
    Peñuelas M; Candel FJ; Lejarraga C; López-González L; Viñuela-Prieto JM; López de Mendoza D
    Rev Esp Quimioter; 2016 Oct; 29(5):255-8. PubMed ID: 27374726
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Prediction of vancomycin pharmacodynamics in children with invasive methicillin-resistant Staphylococcus aureus infections: a Monte Carlo simulation.
    Frymoyer A; Hersh AL; Coralic Z; Benet LZ; Joseph Guglielmo B
    Clin Ther; 2010 Mar; 32(3):534-42. PubMed ID: 20399990
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Are Vancomycin Trough Concentrations of 15 to 20 mg/L Associated With Increased Attainment of an AUC/MIC ≥ 400 in Patients With Presumed MRSA Infection?
    Hale CM; Seabury RW; Steele JM; Darko W; Miller CD
    J Pharm Pract; 2017 Jun; 30(3):329-335. PubMed ID: 27074786
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Comparison of Vancomycin Area-Under-the-Curve Dosing Versus Trough Target-Based Dosing in Obese and Nonobese Patients With Methicillin-Resistant
    Covvey JR; Erickson O; Fiumara D; Mazzei K; Moszczenski Z; Slipak K; Nemecek BD; Zimmerman DE; Guarascio AJ
    Ann Pharmacother; 2020 Jul; 54(7):644-651. PubMed ID: 31888350
    [No Abstract]   [Full Text] [Related]  

  • 72. Hospital Pharmacometrics for Optimal Individual Administration of Antimicrobial Agents for Anti-methicillin-resistant Staphylococcus aureus Infected Patients.
    Tsuji Y
    Biol Pharm Bull; 2021; 44(9):1174-1183. PubMed ID: 34471044
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Efficacy of Telavancin in Comparison to Linezolid in a Porcine Model of Severe Methicillin-Resistant Staphylococcus aureus Pneumonia.
    Battaglini D; Motos A; Li Bassi G; Yang H; Pagliara F; Yang M; Aguilera Xiol E; Meli A; Bobi J; Frigola G; Senussi T; Idone F; Travierso C; Chiurazzi C; Fernandez-Barat L; Rigol M; Ramirez J; Pelosi P; Chiumello D; Antonelli M; Nicolau DP; Bringue J; Artigas A; Guerrero L; Soy D; Torres A
    Antimicrob Agents Chemother; 2020 Dec; 65(1):. PubMed ID: 33046500
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Susceptibility trends including emergence of linezolid resistance among coagulase-negative staphylococci and meticillin-resistant Staphylococcus aureus from invasive infections.
    Decousser JW; Desroches M; Bourgeois-Nicolaos N; Potier J; Jehl F; Lina G; Cattoir V; Vandenesh F; Doucet-Populaire F;
    Int J Antimicrob Agents; 2015 Dec; 46(6):622-30. PubMed ID: 26453147
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Evaluation of once-daily vancomycin against methicillin-resistant Staphylococcus aureus in a hollow-fiber infection model.
    Nicasio AM; Bulitta JB; Lodise TP; D'Hondt RE; Kulawy R; Louie A; Drusano GL
    Antimicrob Agents Chemother; 2012 Feb; 56(2):682-6. PubMed ID: 22083484
    [TBL] [Abstract][Full Text] [Related]  

  • 76. In vivo activity of the pyrrolopyrazolyl-substituted oxazolidinone RWJ-416457.
    Hilliard JJ; Fernandez J; Melton J; Macielag MJ; Goldschmidt R; Bush K; Abbanat D
    Antimicrob Agents Chemother; 2009 May; 53(5):2028-33. PubMed ID: 19273686
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Population pharmacokinetics and target attainment analysis of vancomycin after intermittent dosing in adults with cystic fibrosis.
    Yellepeddi VK; Lindley B; Radetich E; Kumar S; Bhakta Z; Leclair L; Parrot M; Young DC
    Antimicrob Agents Chemother; 2024 Jan; 68(1):e0099223. PubMed ID: 38059634
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Simplified daptomycin dosing regimen for adult patients with methicillin-resistant Staphylococcus aureus infections based on population pharmacokinetic analysis.
    Yamada T; Soda M; Nishida R; Miyake N; Maeshiro Y; Oida Y; Yamashita Y; Egashira N; Shimono N; Kitaichi K; Ieiri I
    Drug Metab Pharmacokinet; 2022 Jun; 44():100444. PubMed ID: 35462110
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Linezolid dosage in pediatric patients based on pharmacokinetics and pharmacodynamics.
    Matsumoto K; Shigemi A; Takeshita A; Watanabe E; Yokoyama Y; Ikawa K; Morikawa N; Takeda Y
    J Infect Chemother; 2015 Jan; 21(1):70-3. PubMed ID: 25305808
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Worrisome trends in rising minimum inhibitory concentration values of antibiotics against methicillin resistant Staphylococcus aureus - Insights from a tertiary care center, South India.
    Niveditha N; Sujatha S
    Braz J Infect Dis; 2015; 19(6):585-9. PubMed ID: 26361841
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.